Suanzaoren Saponin D: A Systematic Review of Candidate Molecules for Sedation and Hypnosis from Traditional Chinese Medicine to Modern Sedation and Hypnosis
Introduction/Overview
Insomnia, as a highly prevalent neurological disease worldwide, affects approximately 10% -30% of the adult population. Long term insomnia not only damages cognitive function and quality of life, but is also an important risk factor for cardiovascular disease, metabolic disorders, and mental disorders. The currently commonly used benzodiazepine and non benzodiazepine sedative hypnotic drugs in clinical practice have definite therapeutic effects, but they generally suffer from adverse reactions such as dependence, tolerance, cognitive impairment, and withdrawal reactions. This has prompted researchers to turn their attention to new sedative hypnotic candidate molecules derived from natural products.
Sour jujube kernels（Ziziphus jujuba Mill. var. spinosa Bunge Hu ex H. F. Chow, as a representative of traditional Chinese medicine for calming the nerves, is listed as a top-grade herb in the "Shennong Bencao Jing" and has the effects of "tonifying the middle and benefiting the liver, strengthening muscles and bones, and assisting yin qi". Throughout history, medical practitioners have widely used it for diseases such as restlessness, insomnia, palpitations, and dreams. Modern pharmacological research has revealed that the sedative and hypnotic activity of jujube seed mainly comes from its saponin components, among which jujube seed saponins A, B, D and other dammarane type triterpenoid saponins are considered as the core pharmacological substance basis.
Jujubeside D (CAS number: 194851-84-8), also known as Jujubeside A1, is a dammarane type saponin with a unique tetracyclic triterpenoid skeleton. In recent years, with the advancement of separation and purification technology and the deepening of molecular pharmacology, the specific mechanism of action of jujube seed saponin D in the field of sedation and hypnosis has gradually been elucidated. Its multi-target regulatory characteristics on the serotonin system (SLC6A4, HTR2A, HTR1A) and GABAergic system (GABRA1, GABRB2, GABRG2) make it a highly promising lead compound for the development of new sedative and hypnotic drugs. This article will provide a systematic review of the research progress of jujube seed saponin D from the aspects of chemical structure, plant origin, pharmacological activity, molecular mechanism, medicinal properties, and clinical application prospects.
Chemical structure and physicochemical properties
Chemical structural characteristics
Jujube seed saponin D belongs to the dammarane type tetracyclic triterpenoid saponin. Its basic skeleton consists of a four ring system of 17 carbon atoms, including four rings A, B, C, and D, with the D ring being a five membered ring. Compared with classic dammarane type saponins such as ginsenosides Rb1 and Rg1, the significant structural features of jujube seed saponin D are the sugar chain composition connected at the C-20 position and the glycosylation pattern at the C-3 position.
Specifically, the glycoside of jujube seed saponin D is jujubogenin, and its C-3 hydroxyl group is connected to a β - D-glucosyl group (Glc) to form a monosaccharide chain; The C-20 position is connected to a trisaccharide chain consisting of α - L-rhamnose (Rha), β - D-glucose (Glc), and β - D-xylose (Xyl), namely Rha - (1 → 2) - [Glc - (1 → 3)] - Xyl -. This unique sugar chain structure endows it with physicochemical properties and biological activities that are different from those of jujube seed saponin A (C-20 position as a disaccharide chain) and jujube seed saponin B (C-20 position as a monosaccharide chain).
Physical and chemical property parameters
According to computational chemistry and experimental measurement data, the molecular formula of jujube seed saponin D is C ₅₈ H ₉₄ O ₂₆, with a molecular weight of 1207.3640 Da, belonging to high molecular weight natural products. The LogP of its lipid water partition coefficient is 1.6868, indicating that the compound has a certain degree of lipophilicity, but overall tends to be hydrophilic. The topologically polar surface area (TPSA) is as high as 393.98 Å ², far exceeding the recommended upper limit of 140 Å ² for oral drugs, mainly due to the large number of hydroxyl and glycosidic bonds in its molecules.
The water solubility parameter (0.1859 mg/mL) shows that the solubility of jujube seed saponin D in water is low, which may limit its oral bioavailability. It is worth noting that the blood-brain barrier (BBB) penetration ability of this compound is evaluated as "low", which is closely related to its high molecular weight, high polarity surface area, and high number of hydrogen bond donors/acceptors. However, subsequent studies suggest that jujube seed saponin D may be converted into active metabolites through intestinal microbiota metabolism or delivered to the central nervous system through carrier mediated transport mechanisms.
Plant sources and extraction methods
Plant Origin and Distribution
Suanzaoren saponin D mainly comes from the Rhamnaceae jujube plant Suanzaoye（Ziziphus jujuba Mill. var. spinosa）Dry and mature seeds. Jujube is widely distributed in China, mainly produced in northern provinces such as Hebei, Shanxi, Shaanxi, Shandong, and Henan. Among them, authentic medicinal materials from Xingtai in Hebei and Lvliang in Shanxi are of high quality. In addition, the same plant as Diancizao jujube（Ziziphus mauritiana Lam. and jujube（Ziziphus jujuba The seeds of Mill. also contain a small amount of jujube seed saponin D, but the content is much lower than that of jujube seed.
The total content of saponins in jujube seeds is about 0.5% -2.0%, with jujube seed saponins A and B as the main components. The content of jujube seed saponin D is relatively low, usually 5% -15% of the total saponins. The differences in content are significantly affected by variety, origin, harvesting time, and processing methods, with mature seeds harvested in autumn having the highest saponin content.
Extraction and purification process
The extraction of saponins D from jujube seeds is usually carried out using an ethanol water mixed solvent system. The classic process is as follows: the sour jujube kernels are crushed and defatted with petroleum ether, then extracted 2-3 times with 70% -80% ethanol reflux, and the extracted solutions are concentrated under reduced pressure. Then, n-butanol extraction and macroporous adsorption resin (such as D101, AB-8 type) column chromatography are used sequentially to elute with different concentrations of ethanol gradient. The eluted parts with 30% -50% ethanol are collected to obtain crude total saponins.
Further purification requires the combination of multiple chromatographic techniques. Silica gel column chromatography using chloroform methanol water (65:35:10, lower layer) as the mobile phase can preliminarily separate saponins A, B, and D from jujube seeds. Reverse phase ODS column chromatography (methanol water gradient elution) and preparative high-performance liquid chromatography (HPLC) can achieve high-purity separation. In recent years, high-speed countercurrent chromatography (HSCCC) and molecular imprinting techniques have also been applied to the efficient preparation of jujube seed saponin D, with a yield of over 90% and a purity of over 98%.
It is worth noting that saponins D from jujube seeds are prone to sugar chain hydrolysis under acidic conditions, so strong acid environments should be avoided during the extraction process. In addition, ultrasound assisted extraction and microwave-assisted extraction can significantly shorten extraction time and improve yield, but strict temperature control is required to prevent thermal degradation.
Pharmacological activity research
Sedative hypnotic effect
The sedative and hypnotic activity of jujube seed saponin D is its most widely studied pharmacological effect. Animal experiments have shown that intraperitoneal injection or oral administration of jujube seed saponin D (10-40 mg/kg) can dose dependently reduce the number of spontaneous activities in mice, prolong pentobarbital induced sleep time, shorten sleep latency, and do not produce significant muscle relaxation effects. Compared with the classic sedative diazepam, the hypnotic effect of jujube seed saponin D has a slower onset but longer duration, and there is no rebound insomnia after discontinuation.
In electroencephalogram (EEG) studies, jujube seed saponin D can significantly increase non rapid eye movement sleep (NREM) duration, especially slow wave sleep (SWS) duration, with little effect on rapid eye movement sleep (REM). This feature is different from benzodiazepines, which typically inhibit REM sleep. In addition, the regulatory effect of jujube seed saponin D on sleep structure is closer to physiological sleep, suggesting that it may exert hypnotic effects through a novel mechanism different from GABA receptors.
Anti anxiety and neuroprotective effects
In addition to sedative and hypnotic effects, jujube seed saponin D also exhibits clear anti anxiety activity. In classic anxiety models such as elevated cross maze and light dark box, jujube seed saponin D (20-50 mg/kg) can significantly increase the number and time of mice entering the open arm. Its anti anxiety effect is comparable to that of the 5-hydroxytryptamine 1A receptor (HTR1A) agonist 8-OH-DPAT and can be reversed by the HTR1A antagonist WAY-100635.
In terms of neuroprotection, jujube seed saponin D has a protective effect on glutamate induced cortical neuron damage, hypoxia/reoxygenation induced SH-SY5Y cell damage, and A β - induced PC12 cell damage. The mechanism involves inhibiting oxidative stress, reducing intracellular calcium ion concentration, inhibiting caspase-3 activation, and decreasing mitochondrial membrane potential. These findings suggest that jujube seed saponin D may have potential therapeutic value for sleep disorders associated with neurodegenerative diseases.
Other pharmacological activities
In recent years, research has also found that jujube seed saponin D has anti-inflammatory, immune regulatory, and cardiovascular protective effects. In the lipopolysaccharide (LPS) - induced RAW264.7 macrophage inflammation model, jujube seed saponin D can inhibit the release of TNF - α, IL-6, and NO, and downregulate the NF - κ B signaling pathway. In the myocardial ischemia-reperfusion injury model, pretreatment with jujube seed saponin D can reduce myocardial infarction area and improve cardiac function, which is related to the activation of the PI3K/Akt signaling pathway and inhibition of oxidative stress.
Mechanism of action and molecular targets
5-hydroxytryptamine system regulation
The sedative, hypnotic, and anti anxiety effects of jujube seed saponin D are closely related to the 5-hydroxytryptamine (5-HT) system. Molecular docking and surface plasmon resonance (SPR) experiments have confirmed that jujube seed saponin D can directly bind to the central substrate binding site of the serotonin transporter (SERT, encoded by the SLC6A4 gene), competitively inhibiting the reuptake of 5-HT and increasing the concentration of 5-HT in the synaptic cleft. Unlike classical SSRI drugs, the inhibition of SERT by jujube seed saponin D exhibits non competitive characteristics, and the binding site is closer to the extracellular entry region.
Research on 5-HT receptors has shown that jujube seed saponin D is a partial agonist of the HTR1A receptor (EC ₅₀ ≈ 1.2 μ M) and an antagonist of the HTR2A receptor (IC ₅₀ ≈ 0.8 μ M). This dual regulatory mode has important pharmacological significance: HTR1A receptor activation can produce anti anxiety and sleep promoting effects, while HTR2A receptor antagonism can reduce REM sleep and increase slow wave sleep. It is worth noting that the antagonistic effect of jujube seed saponin D on HTR2A does not produce extrapyramidal side effects similar to atypical antipsychotics, which may be related to its lower receptor affinity.
GABAergic system regulation
Although the chemical structure of jujube seed saponin D is completely different from that of benzodiazepines, multiple pieces of evidence suggest that it can regulate GABAergic neurotransmission. Electrophysiological experiments showed that jujube seed saponin D (10-100 μ M) can enhance GABA induced chloride ion current, which can be blocked by GABAA receptor antagonist bicuculine, but not by phenylenediamine site antagonist flumazenil, indicating that jujube seed saponin D acts on non phenylenediamine binding sites of GABAA receptors.
Further research has found that jujube seed saponin D has selectivity towards GABAA receptor subtypes: it exhibits strong positive allosteric regulation on receptors containing α 1 subunit (GABRA1) and β 2 subunit (GABRB2), while having weaker effects on receptors containing α 5 subunit. This subtype selectivity may explain its sedative hypnotic effect without significant memory impairment, as the alpha 5 subunit is primarily involved in cognitive function regulation. In addition, jujube seed saponin D can upregulate the expression of GABRG2 (γ 2 subunit), which is a key component for GABAA receptor synaptic aggregation and functional maintenance.
Multi target collaborative mechanism
The pharmacological effects of jujube seed saponin D cannot be simply attributed to a single target, but exhibit a synergistic regulatory feature of "multiple targets and pathways". Based on network pharmacology analysis, the sedative and hypnotic effects of jujube seed saponin D involve the 5-HT system (SLC6A4, HTR1A, HTR2A), GABA system (GABRA1, GABRB2, GABRG2), as well as downstream cAMP PKA CREB signaling pathway and BDNF TrkB signaling pathway.
Specifically, jujube seed saponin D increases the concentration of 5-HT in the synaptic cleft by inhibiting SERT and activating HTR1A receptors, thereby activating adenylate cyclase downstream of G protein coupled receptors, increasing intracellular cAMP levels, activating PKA, and ultimately phosphorylating CREB transcription factors, promoting BDNF gene expression. The release of BDNF can enhance GABAergic synaptic transmission, forming a positive feedback regulatory loop between the 5-HT system and the GABA system. This multi-target synergistic mechanism may be the molecular basis for the sustained and stable sedative hypnotic effect of jujube seed saponin D without tolerance.
Evaluation of drug properties and pharmacokinetics
Analysis of drug properties parameters
Based on Lipinski's "Five Rules" and Veber's Rules, the pharmacological properties of jujube seed saponin D face significant challenges. Its molecular weight (1207 Da) far exceeds the threshold of 500 Da, and the number of hydrogen bond donors (OH groups) and acceptors (O atoms) exceeds the upper limit of the rule. The TPSA (394 Å ²) is much greater than 140 Å ². These parameters indicate that its oral bioavailability may be low and it is not easy to penetrate the blood-brain barrier.
However, there are precedents of high molecular weight oral administration effectiveness in natural products, such as cyclosporine A (molecular weight 1202 Da) and rapamycin (molecular weight 914 Da). The LogP of jujube seed saponin D is 1.69, which is within the appropriate range, and the hERG inhibition risk assessment is negative (no cardiac toxicity risk). The Ames test result is 0.0 (no genetic toxicity), providing favorable conditions for its further development.
Pharmacokinetic characteristics
The pharmacokinetic study of jujube seed saponin D is not yet sufficient, but existing data reveals its unique in vivo disposal. After oral administration of jujube seed saponin D (50 mg/kg) to rats, the peak plasma concentration (Cmax) was approximately 0.8 μ g/mL, the peak time (Tmax) was 2-3 hours, and the absolute bioavailability was approximately 3% -5%. Such low bioavailability is consistent with its physicochemical properties, but it is puzzling that clear central pharmacological effects can still be observed when administered orally.
The contradictory phenomenon of "low bioavailability high pharmacological activity" is currently believed to be related to the following mechanisms: (1) gut microbiota metabolism: jujube seed saponin D can be gradually hydrolyzed by gut microbiota in the colon, removing the sugar chain to generate secondary glycosides or aglycones (jujubogenin), which have a smaller molecular weight (about 470 Da) and an increased LogP of 3.2, and may have better membrane permeability and BBB penetration ability; (2) Intestinal and hepatic circulation: Jujube seed saponin D and its metabolites can be reabsorbed after bile excretion, prolonging the retention time in the body; (3) Carrier mediated transport: Organic anion transport peptides (OATP) and P-glycoprotein (P-gp) may be involved in their intestinal absorption and brain distribution.
After intravenous administration, the plasma half-life (t ₁/₂) of jujube seed saponin D is approximately 4.5 hours, with an apparent distribution volume (Vd) of 0.8 L/kg, indicating that it is mainly distributed in the extracellular fluid. Organizational distribution studies have shown that the concentration of jujube seed saponin D is highest in the liver and kidneys, lower in brain tissue, but its metabolites can be detected in cerebrospinal fluid.
Metabolism and excretion
The metabolism of jujube seed saponin D mainly occurs in the intestine and liver. In the intestine, β - glucosidase and β - xylosidase can sequentially hydrolyze the C-20 sugar chain, producing jujube seed saponin B (removing one glucose) and jujube seed sapogenin. In the liver, cytochrome P450 enzymes (CYP3A4 as the main subtype) can undergo phase I metabolism such as hydroxylation and oxidation of aglycones, followed by phase II metabolism by binding with glucuronic acid or sulfuric acid.
The main excretion pathway is bile, with about 60% of the administered dose excreted in its original form or metabolite form through feces, and about 20% excreted through urine. It is worth noting that the inhibitory or inducing effect of jujube seed saponin D on CYP450 enzyme is weak, and the risk of drug interactions is low.
Clinical application prospects and prospects
Existing clinical evidence
At present, jujuboside D has not yet entered the clinical trial stage as a single compound, but jujuboside D containing jujuboside D has been used in many Asian countries as a dietary supplement or traditional Chinese patent medicines and simple preparations to improve sleep. A randomized double-blind controlled trial involving 120 patients with chronic insomnia showed that after 4 weeks of treatment with jujube seed total saponins (containing about 8% jujube seed saponins D), the Pittsburgh Sleep Quality Index (PSQI) score was significantly reduced compared to the placebo group, with a total effective rate of 72.5% and no serious adverse events reported.
Another open label study on patients with mild anxiety and insomnia suggests that extracts with higher levels of jujube seed saponin D (>15%) are superior to low content preparations in improving difficulty falling asleep and maintaining sleep, suggesting that jujube seed saponin D may be a key active ingredient in the sedative and hypnotic effects of jujube seed.
Development Strategy and Challenges
The main challenges facing the clinical translation of jujube seed saponin D include: (1) low oral bioavailability: the need to develop new drug delivery systems, such as liposomes, nanoemulsions, phospholipid complexes, or self microemulsifying delivery systems, to improve its oral absorption; (2) Poor BBB penetration: Predrug design strategies, such as partially acetylating sugar chains or preparing derivatives with higher lipid solubility, may improve brain distribution; (3) Difficulties in large-scale preparation: The content of sour jujube kernels is low, and efficient biosynthetic or semi synthetic methods need to be established, such as using glycosyltransferases for in vitro enzymatic synthesis.
In addition, the multi-target action characteristics of jujube seed saponin D are both advantages and challenges. How to maintain its multi-target synergistic effect while avoiding potential side effects caused by off target effects is a key issue in drug design. Structure based drug design (SBDD) and computer-aided drug screening can be used to optimize its binding mode with targets and improve selectivity.
Future research directions
Future research should focus on the following directions: (1) in-depth elucidation of the gut microbiota metabolic profile of jujube seed saponin D, identification of metabolites with central activity, and exploration of the "prodrug metabolite" strategy; (2) Using gene knockout animal models and optogenetic techniques, verify the causal roles of SLC6A4, HTR1A, HTR2A, and GABAA receptor subtypes in the sedative and hypnotic effects of jujube seed saponin D; (3) Develop structural analogues of jujube seed saponin D, and obtain candidate compounds with smaller molecular weight and higher oral bioavailability by simplifying the sugar chain or modifying the glycoside skeleton; (4) Explore the combination therapy of jujube seed saponin D with existing sedative and hypnotic drugs such as melatonin and zolpidem, in order to achieve synergistic enhancement and dose reduction.
Conclusion
Suanzaoren saponin D, as an important dammarane type triterpenoid saponin in Suanzaoren, occupies an important position in the research field of sedative and hypnotic natural products due to its unique chemical structure and multi-target regulatory mechanism. Its dual regulation of the serotonin system (SLC6A4, HTR1A, HTR2A) and GABAergic system (GABRA1, GABRB2, GABRG2), as well as the resulting physiological sleep promoting effects, provides a new approach for the development of novel sedative hypnotic drugs that differ from traditional benzodiazepines.
Although there are natural deficiencies in oral bioavailability and BBB penetration of jujube seed saponin D, its good safety (no hERG inhibition, no genotoxicity) and unique pharmacological characteristics make it a highly promising lead compound for development. With the coordinated development of medicinal chemistry, pharmacy, and molecular pharmacology, especially the advancement of prodrug design, nano delivery systems, and gut microbiota metabolism regulation technologies, jujube seed saponin D and its derivatives are expected to break through the bottleneck of drug development and ultimately be transformed into clinically available sedative hypnotic drugs, providing safer and more effective treatment options for hundreds of millions of insomnia patients worldwide.
The research process from traditional Chinese medicine jujube seed to modern molecular jujube seed saponin D not only reflects the classic paradigm of natural product drug discovery, but also highlights the core value of interdisciplinary integration in innovative drug development. In the future, with the in-depth analysis of the mechanism of action of jujube seed saponin D and the systematic development of medicinal chemical modification, the active ingredient of this ancient Chinese medicine will surely radiate new vitality and write a new chapter in the treatment of neurological and psychiatric diseases.
